Finanzen von Humacyte Inc (HUMA)HUMAHumacyte Inc

Evaluating the bottom line, Humacyte Inc maintains a gross margin of -203.20%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -6649.26%, while the net margin is -9064.53%. These profitability ratios, combined with a Return on Equity (ROE) of -547.87%, provide a clear picture of how effectively HUMA converts its operational activities into shareholder value.

In the context of the broader market, HUMA competes directly with industry leaders such as CYPH and SPRB. With a market capitalization of $178.40M, it holds a significant position in the sector. When comparing efficiency, HUMA's gross margin of -203.20% stands against CYPH's N/A and SPRB's N/A. Such benchmarking helps identify whether Humacyte Inc is trading at a premium or discount relative to its financial performance.

Humacyte has shown fluctuating revenues with a notable increase to $753000 in Q3 2025 but has also reported substantial net income losses, peaking at -36802000 in Q2 2026. The gross margin has been highly variable, with a high of 71.57% in Q1 2025 but turning negative in subsequent quarters, indicating operational challenges.